MDL Mass Tort & Class Action Monitor
Developed to serve primarily as a litigation scouting report for plaintiff and defense counsel, insurers and legal service providers, HarrisMartin’s MDL Mass Tort & Class Action Monitor covers significant new filings and decisions in the JPML, MDL and related mass tort arenas. The quick delivery of breaking news and additional features will keep you within close range of every development occurring in the high-stakes environment of mass torts litigation — where minutes can make a difference. The MDL Mass Tort & Class Action Monitor is an online-only offering that includes frequent email updates and is available at no charge to annual and event sponsors of HarrisMartin’s CLE Conferences.
SEARCH THE ARCHIVES
Issue #32, October 2019
The U.S. Judicial Panel on Multidistrict Litigation will hear the petition to create a MDL docket for claims relating to Allergan’s Biocell textured breast implants at its December 4 hearing in Austin, according to a recent hearing session order.
The Food and Drug Administration has recommended a boxed warning for saline and silicone gel-filled breast implants, which would caution doctors and patients of the risk of breast implant-associated anaplastic large cell lymphoma.
In a new lawsuit, a Colorado man contends his long-term ingestion of Zantac (ranitidine) caused him to develop bladder cancer because the antacid drug contains “staggering amounts” of N-nitrosodimethylamine (NDMA), a probable carcinogen.
Attorneys general from four states have announced that they reached a $48 billion settlement framework with Cardinal Health, McKesson Corp., AmerisourceBergen Corp., Johnson & Johnson and Teva Pharmaceuticals over their alleged role in the opioid epidemic.
Drug maker Sanofi has announced that it is voluntarily recalling its over-the-counter heartburn drug Zantac (ranitidine) amid concerns that it was contaminated by a probable human carcinogen known as N-nitrosodimethylamine (NDMA).
A Massachusetts judge has refused to lift a four-month statewide ban on sales of all vaping products, rejecting a national trade association’s argument that it is unconstitutional and “will irreparably destroy Massachusetts’ $331 million nicotine-vapor products industry and the livelihoods of the 2,500 workers that it employs.”
Teva Pharmaceuticals and several drug distributors have agreed to a settlement with two Ohio counties on the eve of the first bellwether trial on the opioid multidistrict litigation docket, sources told HarrisMartin Publishing.
A New Mexico federal judge has granted plaintiffs’ request to trifurcate a trial involving the 2015 spill of three million gallons of contaminated water from the shuttered Gold King Mine in Colorado.
The Ohio federal judge overseeing the opioid multidistrict litigation docket has denied Teva Pharmaceuticals’ request to be severed from the Track One bellwether trial, saying he “is confident the parties will be able to present their case to the jury in an intelligible way.”
The mother of a teenager whose death was allegedly caused by his three-year addiction to vaping has sued JUUL Labs Inc. in California federal court, accusing it of aggressively marketing its product to youths and creating an epidemic.